Blog - The mRNA Synthesis

Stability, Durability, and the "Scar-Free" Manufacturing Frontier The clinical triumph of linear mRNA during the pandemic proved that RNA could be a "sprinter"—rapidly deployed and highly effective for transient immune activation. However, as the industry pivots in...

In February 2026, the mRNA and cell therapy sectors witnessed a strategic shift toward in vivo applications and more durable RNA constructs. As multinational pharmaceutical companies (MNCs) seek to overcome the logistical hurdles of traditional CAR-T, the spotlight...

In January 2026, a cluster of Nipah virus (NiV) cases emerged in West Bengal, India, resulting in five confirmed infections and nearly a hundred individuals under observation. Neighboring countries have already initiated border screenings, as this "Priority Pathogen"...

Chimeric Antigen Receptor (CAR) T-cell therapy has already revolutionized the fight against blood cancers, but its current form—a complex, expensive, and time-intensive process that involves extracting a patient's T cells, shipping them to a lab for engineering (ex...

As the field of mRNA therapeutics continues to expand—spanning vaccines, oncology, protein replacement, and gene editing—scientists are constantly optimizing their tools to improve safety, efficacy, and durability. One of the most impactful innovations in this space...

Self-amplifying RNA (saRNA) is gaining momentum as the next frontier in RNA therapeutics and vaccine development. By integrating an RNA replicon system derived from alphaviruses, saRNA enables amplification of the target antigen in vivo, potentially reducing the...

Supporting Innovation from Research to Clinical Manufacturing In the rapidly evolving field of RNA therapeutics, precise and efficient delivery remains a critical challenge—especially for systemic administration. At Areterna, we are helping solve this challenge by...

As we step into 2025, we have entered the next era of RNA therapeutics. The global biotech and pharmaceutical industries are increasingly integrating mRNA-based medicines and the undeniable potential of RNA into their discovery and development pipelines. While the...

Stay ahead in mRNA research and development with our newly available capped and uncapped reference standards! A linear mRNA molecule primarily consists of five components: the 5' cap structure (5' Cap), the 5' untranslated region (5' UTR), the open reading frame...

Introduction Modified nucleoside triphosphates (NTPs) are the master keys that unlock the therapeutic potential of mRNA. By strategically incorporating these chemically modified building blocks during mRNA synthesis, researchers can enhance stability, translation...